The pharmaceutical industry thrives on innovation, with intellectual property rights playing a crucial role in protecting groundbreaking ideas and ensuring global access to life-saving medicines. As advancements in biotechnology and personalised medicine continue to evolve, the legal landscape also needs to progress to address new ethical considerations and public health challenges.
On these lines, the 13th Annual Pharma IPR Conference was organised by CPHI and Informa Markets from March 5-7, 2024, in Mumbai, exploring topics such as trends and developments in pharma patent litigation, safeguarding pharma patents and sensitive intellectual property data from cyber threats, patent strategies for emerging technologies and biologics, IPR challenges and opportunities in the era of AI, Blockchain, and Big Data in pharma, advancements in genetics, genomics, and precision medicine, the role of trademarks in branding and market positioning, and trends and challenges in polymorph litigations.
Shikha Singh from LexOrbis participated as a speaker during the session on “Emerging Challenges in Gene and Cell Therapies: IP Protection and Ethical Considerations”, addressing the complexities of the intellectual property landscape in the rapidly evolving field of gene and cell therapies, while emphasising the ethical considerations accompanying these groundbreaking treatments.
LexOrbis was also represented by Manisha Singh, Abhai Pandey, and Gaurav Phadnis, where they actively engaged in meaningful discussions, developing valuable connections with global leaders, innovators, and entrepreneurs.